Thursday 16 October, 2025
Objective: The aim of this study was to develop a population pharmacokinetic (PPK) model of piperacillin (PIP) administered to patients…
Read morePoster: Infection
Population pharmacokinetic analysis of colistin in burn patients
Thursday 16 October, 2025
Objectives: Colistin is increasingly used as salvage therapy of nosocomial infections caused by multidrug-resistant gram-negative bacteria such as Psuedomonas aeruginosa…
Read moreA Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells
Thursday 16 October, 2025
Objectives: In a non-tuberculosis infected population describe rifampicin´s (RIF) autoinduced plasma concentrations and predict the concentration ratios between epithelial lining…
Read moreDevelopment of population pharmacokinetic model for Tenofovir using sparsely sampled subject data
Thursday 16 October, 2025
Objectives: The study was performed to investigate gender differences in the pharmacokinetics of Tenofovir from the Partners pre-exposure prophylaxis (PrEP)…
Read moreSimultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies
Thursday 16 October, 2025
Objectives: Atazanavir (ATV) is a protease inhibitor (PI) used as part of combination HIV therapy. ATV is metabolised by CYP3A4/3A5….
Read morePopulation pharmacokinetic of rifampicine in Malawian children.
Thursday 16 October, 2025
Objectives: Rifampicine (RIF) is considered a key drug for the treatment of pulmonary infections caused by M. tuberculosis. It rapidly…
Read moreComparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro.
Thursday 16 October, 2025
Objectives: Already early in the preclinical phase, resistance development of bacteria against antibacterials can be observed. The use of dynamic…
Read moreApplying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN
Thursday 16 October, 2025
Objectives: Mathematical models have been widely used for understanding viral dynamics of hepatitis C virus (HCV) [1,2]. An adapted model…
Read moreMechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy
Thursday 16 October, 2025
Objectives: Polymyxins have become the last line of defence against multidrug resistant Pseudomonas aeruginosa and other gram-negative bacteria. Polymyxin B…
Read morePharmacokinetics of doripenem in cerebrospinal fluid
Thursday 16 October, 2025
Objectives: To characterise the pharmacokinetics of the antibiotic doripenem (DRP) in cerebrospinal fluid (CSF). Methods: 44 neurological patients received a…
Read more